Results 161 to 170 of about 34,967 (216)

Efficacy and safety of rivaroxaban plus aspirin compared with aspirin alone in patients with peripheral arterial disease: a systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Farhan M, Ali SH, Khalid D, Kazmi A, Asim D, Idrees Z, Siddiqui MS, Sohaib SB, Khan MS, Khan MM, Mahmoud A.   +10 more
europepmc   +1 more source

Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case-control study. [PDF]

Ther Adv Drug Saf
Yodsurang V, Wattanathum K, Srimatimanon T, Pitinanon K, Ranti A, Siripattarachai P, Hirunpatrawong P, Rungpradubvong V, Sakamoto S, Sujarit AS.   +9 more
europepmc   +1 more source

Anticoagulation Stewardship in the Era of Practice-Changing Evidence: A Narrative Review of Recent Trials and Their Bedside Translation. [PDF]

J Clin Med
Aljabry M, Alotaibi G.
europepmc   +1 more source

TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short. [PDF]

Blood Adv
Crossette-Thambiah C, Bamberg K, Laffan M, Ahnström J.   +3 more
europepmc   +1 more source

Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation. [PDF]

Clin Pharmacokinet
Lai NS, Lin CJ, Kuo CH, Peng YF, Tang SC, Huang CF, Lin SY, Lin SW.   +7 more
europepmc   +1 more source

Rivaroxaban for extended anticoagulation of pediatric venous thromboembolism. [PDF]

Transl Pediatr
Pelland-Marcotte MC, Zabeida A.
europepmc   +1 more source

Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Feng Y, Liu HH, Li LC, Mao KL, Niu XF, Hu J.   +5 more
europepmc   +1 more source

Extended-phase anticoagulation for pediatric venous thromboembolism after EINSTEIN Jr. [PDF]

Transl Pediatr
Wilken N, Teruya J.
europepmc   +1 more source

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11). [PDF]

Br J Clin Pharmacol
Isoardi KZ, Chiew AL, Harris K, Isbister GK.   +3 more
europepmc   +1 more source

Real-world bleeding risk and molecular interaction profiles of direct oral anticoagulants: a comparative study integrating clinical outcomes and <i>in silico</i> docking. [PDF]

Front Pharmacol
Onar LC, Guner E, Yilmaz I.
europepmc   +1 more source